{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.0","upperLimit":"32.9","value":"27.2"},{"groupId":"OG001","lowerLimit":"5.3","upperLimit":"16.1","value":"9.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"272"},{"groupId":"OG001","value":"133"}],"units":"Participants"}],"description":"Objective response rate (ORR) per Independent Review Committee (IRC) is defined as the number of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the number of randomized participants using RECIST 1.1","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg IV over 60 minutes Q2W","id":"OG000","title":"Nivolumab"},{"description":"Dacarbazine: 1000 mg/m\\^2 IV over 30 to 60 minutes Q3W, or Carboplatin: Area under the concentration-time curve (AUC) 6 IV over 30 minutes Q3W, and Paclitaxel: 175 mg/m\\^2 IV over 180 minutes Q3W","id":"OG001","title":"Investigator's Choice (Dacarbazine or Carboplatin+Paclitaxel)"}],"paramType":"NUMBER","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From date of randomization to the date of objectively documented progression, date of death, or the date of subsequent therapy (Up to approximately 38 months)","title":"Objective Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}